Skip to main content
. 2026 Oct 29;17:1947706. doi: 10.3389/fpsyt.2026.1947706

Table 1.

Demographic and clinical characteristics, treatment and CGI outcomes of the patients (N = 650).

Characteristic n (%)
Age, years, mean ± SD 13.23 ± 3.18
Age group
4–10 years 135 (20.8)
11–14 years 230 (35.4)
15–17 years 285 (43.8)
Sex
Female 383 (58.9)
Male 267 (41.1)
Psychiatric comorbidity
Yes 467 (71.8)
No 183 (28.2)
Physical comorbidity
Yes 38 (5.8)
No 612 (94.2)
Labelling status of current antidepressant regimen (FDA)
On-label 164 (25.2)
Off-label 486 (74.8)
Labelling status of first antidepressant (FDA)
On-label 179 (27.5)
Off-label 471 (72.5)
Labelling status of second antidepressant (FDA), n = 87
On-label 19 (21.8)
Off-label 68 (78.2)
CGI-Severity at treatment initiation
Mildly ill (3) 29 (4.5)
Moderately ill (4) 424 (65.2)
Markedly ill (5) 197 (30.3)
CGI-Improvement at last recorded follow-up
Positive response (score 1–2) 550 (84.6)
 Very much improved (1) 311 (47.8)
 Much improved (2) 239 (36.8)
Partial response: minimally improved (3) 100 (15.4)
Concomitant psychotropic treatment
No (monotherapy) 365 (56.2)
Yes 285 (43.8)
Any adverse effect
Yes 139 (21.4)
No 511 (78.6)
Prior antidepressant trial
Yes 88 (13.5)
No 562 (86.5)
Reason for discontinuation of prior antidepressant, n = 88
Lack of efficacy 63 (71.6)
Partial efficacy 10 (11.4)
Adverse effects 15 (17.0)

Percentages are calculated with N = 650 as the denominator unless another denominator (n) is stated. CGI, Clinical Global Impression; FDA, U.S. Food and Drug Administration; SD, standard deviation. Labelling status was classified according to FDA paediatric labelling (drug, indication and age). Prior antidepressant trial: discontinuation of an earlier antidepressant followed by a switch to another agent (the discontinued agent was an SSRI in 84 of 88 patients).